What are non target lesion in RECIST criteria for response to chemotherapy in breast cancer
I'll read the medical library skill first, then search for RECIST criteria information.
Reading File
Now let me search the library and web in parallel.
Finding Sources
Finding Sources
Searching the Web
RECIST 1.1 non-target lesion criteria definition response assessment
I found the relevant Washington Manual section. Let me read it and also search for more specific breast cancer RECIST content.
Reading File
Finding Sources
I now have comprehensive information to provide a detailed answer. Let me compile everything.
Non-Target Lesions in RECIST 1.1 Criteria
Definition
Non-target lesions are all lesions (or sites of disease) that are not selected as target lesions at baseline. This includes:
- All non-measurable lesions (lesions too small to measure reliably: <10 mm on CT/MRI for non-nodal lesions, or lymph nodes with short axis <15 mm but still pathological)
- Pathological lymph nodes not selected as target lesions
- Lesions that are measurable but were not chosen as target lesions (RECIST allows up to 5 total target lesions, max 2 per organ)
- Sites of disease such as leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast cancer, lymphangitic spread, and abdominal masses not confirmed by imaging
How Non-Target Lesions Are Followed
Unlike target lesions, non-target lesions do not require measurements. They are tracked qualitatively as:
| Status | Meaning |
|---|---|
| Present | Lesion still visible but not progressing |
| Absent | Lesion has disappeared |
| Unequivocal progression | Clear, substantial worsening (rare) |
Response Categories for Non-Target Lesions
| Response | Definition |
|---|---|
| Complete Response (CR) | Disappearance of ALL non-target lesions AND normalization of tumor marker levels. All lymph nodes must be non-pathological in size (<10 mm short axis). |
| Non-CR / Non-PD | Persistence of one or more non-target lesion(s) AND/OR maintenance of tumor marker levels above the normal limit. This is the most common category - it means the disease has neither fully resolved nor clearly progressed. |
| Progressive Disease (PD) | Unequivocal progression of existing non-target lesions. |
Key Rule: "Unequivocal Progression"
This is the most nuanced part of non-target assessment:
- A modest increase in size of one or more non-target lesions is NOT sufficient to declare progression
- There must be an overall level of substantial worsening such that - even if target lesions show SD or PR - the overall tumor burden has clearly increased enough to warrant stopping therapy
- Progression based solely on non-target disease (when target lesions are stable or responding) is extremely rare in practice
- The appearance of new lesions always constitutes PD, regardless of non-target or target status
Overall Response Integration (Target + Non-Target)
| Target Response | Non-Target Response | New Lesions | Overall Response |
|---|---|---|---|
| CR | CR | No | CR |
| CR | Non-CR/Non-PD | No | PR |
| CR | Not evaluated | No | PR |
| PR | Non-PD or not evaluated | No | PR |
| SD | Non-PD or not evaluated | No | SD |
| PD | Any | Any | PD |
| Any | PD | Any | PD |
| Any | Any | Yes | PD |
Special Notes for Breast Cancer
- Bone metastases are common in breast cancer and are classified as non-target lesions if blastic (non-measurable) - only lytic lesions with a measurable soft tissue component qualify as target lesions
- Inflammatory breast cancer (skin involvement, dermal lymphatics) is considered non-measurable and tracked as a non-target lesion
- Lymphangitic carcinomatosis (lung/skin) is non-measurable - non-target
- Pleural/pericardial effusion is non-measurable - non-target
- Tumor markers (CA 15-3, CA 27-29) are factored into non-target CR assessment (must normalize for CR)
- Brain metastases: if previously irradiated, may not count as new lesions; if new and unirradiated, constitute PD
Practical Points
- Non-target lesions can never "switch" to target lesions during the course of treatment - the lesion designations at baseline are fixed
- Multiple non-target lesions in the same organ can be recorded as a single line item (e.g., "multiple liver metastases")
- A lesion that was a target lesion and becomes "too small to measure" is recorded as 0 mm (or 5 mm by convention) - it does not become a non-target lesion
- Non-target lymph nodes should only be designated as such if short axis is ≥1 cm; nodes <1 cm cannot achieve formal CR by RECIST definition if listed as non-target
- Washington Manual of Medical Therapeutics, Table 22-4 (RECIST 1.1 summary)
- RECIST 1.1 Official Guideline (EORTC)
- Pearls and pitfalls of RECIST v1.1 non-target lesion assessment (PMC7771310)
This is a shared conversation. Sign in to Orris to start your own chat.